Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.61
(0.29%)
CNY 44.61
(0.29%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 434.22 Million CNY | -40.81% |
| 2022 | 733.61 Million CNY | 80.32% |
| 2021 | 406.83 Million CNY | 45.81% |
| 2020 | 279.02 Million CNY | 80.89% |
| 2019 | 154.25 Million CNY | 4394.87% |
| 2018 | 3.43 Million CNY | -80.31% |
| 2017 | 17.42 Million CNY | 7.81% |
| 2016 | 16.16 Million CNY | 124.49% |
| 2015 | 7.19 Million CNY | -38.9% |
| 2014 | 11.78 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 434.74 Million CNY | 0.12% |
| 2024 Q2 | 404.81 Million CNY | -6.88% |
| 2024 Q3 | 397.23 Million CNY | -1.87% |
| 2023 Q2 | 741.67 Million CNY | -0.75% |
| 2023 Q4 | 434.22 Million CNY | -54.52% |
| 2023 FY | 434.22 Million CNY | -40.81% |
| 2023 Q3 | 954.68 Million CNY | 28.72% |
| 2023 Q1 | 747.3 Million CNY | 1.87% |
| 2022 Q3 | 575.96 Million CNY | 29.24% |
| 2022 Q2 | 445.64 Million CNY | 11.88% |
| 2022 Q4 | 733.61 Million CNY | 27.37% |
| 2022 Q1 | 398.32 Million CNY | -2.09% |
| 2022 FY | 733.61 Million CNY | 80.32% |
| 2021 Q3 | 375.18 Million CNY | 15.84% |
| 2021 FY | 406.83 Million CNY | 45.81% |
| 2021 Q2 | 323.88 Million CNY | 14.43% |
| 2021 Q4 | 406.83 Million CNY | 8.44% |
| 2021 Q1 | 283.04 Million CNY | 1.44% |
| 2020 Q1 | 380.4 Million CNY | 146.61% |
| 2020 Q3 | 237.15 Million CNY | -37.48% |
| 2020 FY | 279.02 Million CNY | 80.89% |
| 2020 Q4 | 279.02 Million CNY | 17.65% |
| 2020 Q2 | 379.32 Million CNY | -0.28% |
| 2019 Q2 | 91.58 Million CNY | 3980.03% |
| 2019 Q4 | 154.25 Million CNY | -12.03% |
| 2019 FY | 154.25 Million CNY | 4394.87% |
| 2019 Q1 | 2.24 Million CNY | -34.59% |
| 2019 Q3 | 175.34 Million CNY | 91.47% |
| 2018 Q4 | 3.43 Million CNY | -25.17% |
| 2018 FY | 3.43 Million CNY | -80.31% |
| 2018 Q3 | 4.58 Million CNY | -16.82% |
| 2018 Q2 | 5.51 Million CNY | -65.69% |
| 2018 Q1 | 16.06 Million CNY | -7.78% |
| 2017 FY | 17.42 Million CNY | 7.81% |
| 2017 Q1 | 6.16 Million CNY | -61.83% |
| 2017 Q2 | 16.08 Million CNY | 160.78% |
| 2017 Q4 | 17.42 Million CNY | -29.18% |
| 2017 Q3 | 24.6 Million CNY | 52.94% |
| 2016 Q4 | 16.16 Million CNY | 164.96% |
| 2016 Q3 | 6.1 Million CNY | 7.02% |
| 2016 Q2 | 5.7 Million CNY | -14.54% |
| 2016 FY | 16.16 Million CNY | 124.49% |
| 2016 Q1 | 6.66 Million CNY | -7.36% |
| 2015 Q2 | 19.12 Million CNY | 57.41% |
| 2015 Q3 | 7.5 Million CNY | -60.76% |
| 2015 Q4 | 7.19 Million CNY | -4.08% |
| 2015 Q1 | 12.15 Million CNY | 3.12% |
| 2015 FY | 7.19 Million CNY | -38.9% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 11.78 Million CNY | 165.65% |
| 2014 Q3 | 4.43 Million CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2014 FY | 11.78 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 2.33 Billion CNY | 81.365% |
| Dirui Industrial Co.,Ltd. | 3.66 Million CNY | -11741.358% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 61.63% |
| Medicalsystem Biotechnology Co., Ltd. | 23.59 Million CNY | -1740.243% |
| Maccura Biotechnology Co.Ltd | 175.47 Million CNY | -147.452% |
| Guangzhou Wondfo Biotech Co.,Ltd | 580.52 Million CNY | 25.202% |
| Guangdong Hybribio Biotech Co.,Ltd. | 28.26 Million CNY | -1436.069% |
| BGI Genomics Co., Ltd. | 283.42 Million CNY | -53.205% |
| Amoy Diagnostics Co., Ltd. | 44.4 Million CNY | -877.98% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 166.83 Million CNY | -160.268% |